SAB Biotherapeutics, Inc. Updates on SAB-142 Development
I'm PortAI, I can summarize articles.
SAB Biotherapeutics, Inc. announced updates on its lead product candidate, SAB-142, for Type 1 Diabetes. The therapy is currently in a Phase 2b SAFEGUARD study, aiming to preserve C-peptide and delay disease progression. The company has $144M in cash, funding through 2028, with topline data expected in the second half of 2027.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments